

## Special Issue

# Targeted Radiotracers for Molecular Imaging and Therapy in Cancer

### Message from the Guest Editors

Targeted radiotracers are vital in precision oncology, allowing non-invasive visualization and treatment of diverse cancers. These agents, comprising radionuclides linked to peptides, antibodies, or small molecules, selectively bind to cancer-associated targets such as somatostatin receptors, PSMA, HER2, CXCR4, and integrins. They enable patient stratification, personalized therapy, and treatment response assessment. This Special Issue highlights recent advances in the design, evaluation, and clinical translation of targeted radiotracers for diagnostic and therapeutic use. Emphasis is placed on the *theranostic* concept—using the same molecular scaffold for both imaging and therapy—as exemplified by  $^{68}\text{Ga}$ -/ $^{177}\text{Lu}$ -labeled PSMA and DOTATATE. Such approaches enhance treatment planning, dosimetry, and response monitoring. Expanding radiotracer development continues to strengthen their role in oncology. This Special Issue provides an overview of current challenges and future directions in molecular imaging and targeted radionuclide therapy.

---

### Guest Editors

Prof. Dr. Vladimir Tolmachev

Department of Immunology, Genetics and Pathology (IGP), Uppsala University, 751 85 Uppsala, Sweden

Dr. Maryam Oroujeni

Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden

---

### Deadline for manuscript submissions

30 June 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/246301](https://mdpi.com/si/246301)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)